Sorafenib in patients with child-pugh class A and B advanced hepatocellular carcinoma: A prospective feasibility analysis

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 406-411

  Pressiani, T ^a   Boni, C ^b   Rimassa, L ^a   Labianca, R ^c   Fagiuoli, S ^c   Salvagni, S ^d   Ferrari, D ^e   Cortesi, E ^f   Porta, C ^g   Mucciarini, C ^h   Latini, L ⁱ   Carnaghi, C ^a   Banzi, M ^b   Fanello, S ^b   De Giorgio, M ^c   Lutman, F R ^a   Torzilli, G ^j   Tommasini, M A ^a   Ceriani, R ^a   Covini, G ^a   Tronconi, M C ^a   Giordano, L ^a   Locopo, N ^a   Naimo, S ^a   Santoro, A ^a   more..

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e SAN PAOLO HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h Hospital Ramazzini   (Italy)

ⁱ Hospital of Macerata   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Carcinoma; Child Pugh class; Cirrhosis; Hepatocellular; Sorafenib

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CACHEXIA; CANCER LOCALIZATION; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HAND FOOT AND MOUTH DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; STOMATITIS; TREATMENT DURATION; VASCULAR DISEASE; WEIGHT REDUCTION;

EID: 84873834330     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds343     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Raoul JL, Sangro B, Forner A et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37(3): 212-220.
3. Keating GM, Santoro A. Sorafenib. A review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69(2): 223-240.
4. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-390.
5. Alves RC, Alves D, Guz B et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepato 2011; 10(1): 21-27.
6. Simpson D, Keating GM. Sorafenib in hepatocellular carcinoma. Drugs 2008; 68 (2): 251-258.
7. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25-34.
8. Peck-Radosavljevic M, Greten TF, Lammer J et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22(4): 391-398.
9. Abou-Alfa GK, Amadori D, Santoro A et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4(2): 40-44.
10. Kim JE, Ryoo BY, Tyu MH et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011; 68(5): 1285-1290.
11. Hollebecque A, Cattan S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 10: 1193-1201.
12. Wörns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43(5): 489-495.
13. Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14(1): 70-76.
14. Marrero JA, Lencioni R, Kudo M et al. Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29(Suppl): Abstract 4001.
15. Iavarone M, Cabibba G, Piscaglia F et al. Field practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54(6): 2055-2063.
16. Basso M, Basso M, Barone C. Sorafenib in clinical practice: evidence-based use or abuse? Hepatology 2012; 55(4): 1305.
17. Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27(11): 1800-1805.
18. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24(26): 4293-4300.
19. Pressiani T, Rimassa L, Boni C et al. Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol 2011; 29(Suppl): Abstract 4115.
20. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009; 9(6): 739-745.
21. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009; 29(4): 502-510.
22. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44 (1): 217-231.